E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Interictal delirium during electric convulsive therapy- course |
Interictaal delier tijdens electro convulsieve therapie |
|
E.1.1.1 | Medical condition in easily understood language |
Delirium during and due to electro convulsive therapy-course (ECT). Delrium is a (sub)acute and severe confusional state and a reaction of the brain to in this study ECT |
Delier tijdens en veroorzaakt door electroconvulsieve therapie (ECT). Een delier is een (sub)acute en ernstige verwardheid en een ractie van het brein op, in deze studie, ECT |
|
E.1.1.2 | Therapeutic area | Psychiatry and Psychology [F] - Mental Disorders [F03] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The aim of this study is twofold. The main aim of this study is twofold. We aim to (1) investigate whether rivastigmine can be used as a novel treatment to reduce ECT-induced interictal delirium and (2) to gain further insight in the different types of cognitive disturbances induced by ECT and its correlates by creating a large cohort of ECT patients. |
Het doel van het onderzoek is tweeledig:
Ten eerste 1) willen wij onderzoeken of rivastigmine kan worden toegepast als de behandeling van het interictaal delier en
ten tweede 2) willen wij meer inzicht verkrijgen in de verschillende typen van ECT-geinduceerde cognitieve stoornissen door een groot cohort te realiseren van ECT patienten |
|
E.2.2 | Secondary objectives of the trial |
To describe
- influence rivastgmine on several ECT and anaesthetic parameters (sedation, medication use, reorientation time, effects on muscle relaxation, bloodpressure, etc)
- tolerability of rivastigmine during ECT
For differentiation into subtypes of confusional states and their determinants:
- Profiles of confusional states based on scores on reorientation time, Richmond Agitation Sedation Scale (RASS), Confusion Assessment Methods (CAM)/Delirium Rating Scale (DRS-98), MMSE, fluency, clock-drawing-test, all assessed during ECT, and their determinants. |
Beschrijven van
- effect rivastigmine op verschillende ECT en anesthesie parameterts (sedatie, medicatie gebruik, reorientatie tijd, effecten op spierrelaxatie, bloeddruk, ect)
- Tolerantie rivastigmine gedurende ECT
Ter onderscheiding verschillende typen ECT geinduceerde cogntieve stoornissen:
- Profielen schetsen obv scores op reorientatietijd, Richmond Agitation Sedation Scale (RASS), Confusion Assessment Methods (CAM)/Delirium Rating Scale (DRS-98), MMSE, fluency, kloktekentest gedurende ECT |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Patient is admited at the in-wards of one of the participating psychiatric hospitals
- Patients fulfilling the Composite International Diagnostic Interview (CIDI) criteria of a Major Depressive Episode (not necessarily in the context of a Major Depressive Disorder only)
- Patient is indicated for ECT-treatment.
- Patient or legal representitive is able to give informed consent
- Occurence of an interictal delirium is assessed by the Confusion Assessment method (CAM) and/ or 4 pts drop Mini Mental State Examination score (MMSE) |
- patient is opgenomen op de opnameafdeling van de een van de deelnemende psychiatrische ziekenhuizen
- Patient voldoet aan Composite International Diagnostic Interview (CIDI) criteria van een ernstige depressieve episode, niet noodzakelijkerwijs in de context van alleen een ernstige depressieve stoornis
- Patient of wettelijk vertegenwoordiger is in staat tot geven informed consent
- Optreden van interictaal delier volgens de Confusion Assessment method (CAM) en/of 4 punten daling Mini Mental State Examination score (MMSE) |
|
E.4 | Principal exclusion criteria |
- Patients not meeting the inclusion criteria
- Patient has a comorbid medical condition that is a contraindication for ECT according to the prevailing Dutch ECT-guidelines
- Current use of rivastigmine or an other cholinesterase inhibitor
- Known intolerance of rivastigmine or an other cholinesterase inhibitor
- Bradycardia or AV conduction disorder at baseline ECG (first degree AV block exluded)
- switch from right unilateral electrodeplacement (RUL) to bilateral electrodeplacement (BL) during trial |
- Patient voldoet niet aan inclusie criteria
- Aanweizigheid van comorbiditeit die geldt als contra indicatie voor ECT volgends de huidige Nederlandse ECT richtlijn
- Gelijktijdig gebruik van rivastigmine of een andere cholinesteraseremmer
- Bekende intolerantie voor rivastigmine of een andere cholinesteraseremmer.
- Bradycardie danwel AV geleidingsstoornis op baseline ECG (excl 1e graads AV blok)
- switch van uni naar bilaterale electrodeplaatsing tijdens ECT |
|
E.5 End points |
E.5.1 | Primary end point(s) |
1. Scores on Delirium Rating Scale (DRS-98), assessed after two ECT sessions with rivastigmine, compared with DRS-98 outcomes assessed after two ECT sessions without rivastigmine .
2. Scores on cognitive functioning tests (MMSE, fluency, clock-drawing-test), assessed after two ECT sessions with rivastigmine, compared with outcomes assessed after two ECT sessions without rivastigmine.
NB baseline scores: mainained 48-24h before first ECT session within trial.
|
Primaire uitkomsten
1. Score op Delirium Rating Scale (DRS 98) bepaald na 2x ECT met rivastgmine, vergeleken met DRS score na 2X ECT zonder rivastigmine en baseline scores
2. Scores op multipele cognitieve testen (MMSE, fluency en kloktekentest) bepaald na 2x ECT met rivastgmine, vergeleken met DRS score na 2X ECT zonder rivastigmine en baseline scores
NB baseline sores: verkregen 48-24uur voor de eerste ECT sessie in de trial |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Final scores will be obtained 1 day after the final ECT session in the trial |
Laaste scores worden verkregen 1 dag na de laatste ECT sessie binnen de trial |
|
E.5.2 | Secondary end point(s) |
3.Impact of rivastigmine on several ECT characteristics (bloodpressure, heart rate, seizure length, post ictal supression index, seizure threshold, time of – anesthesia induced - muscle relaxation, type of anesthetics and dosage) measured during ECT.
4.Adverse/ side effects of rivastigmine.
For differentiation into subtypes of confusional states and their determinants:
5. Profiles of confusional states based on scores on reorientation time, Richmond Agitation Sedation Scale (RASS), Confusion Assessment Methods (CAM)/Delirium Rating Scale (DRS-98), MMSE, fluency, clock-drawing-test, all assessed during ECT, and their determinants.
|
3. Effect van rivastigmine op verscheidene ECT paramaters (bloeddruk, hartslag, insult duur, post ictale suppressie index, prikkeldrempel, spierrelaxatie, type anesthetica en dosis) gedurende ECT
4. Bijwerkingen
Ter onderscheiding verschillende typen ECT geinduceerde cogntieve stoornissen:
- Profielen schtesen obv scores op reorientatietijd, Richmond Agitation Sedation Scale (RASS), Confusion Assessment Methods (CAM)/Delirium Rating Scale (DRS-98), MMSE, fluency, kloktekentest gedurende ECT |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Final scores for secondary endpoint will be obtained 1 day maximum after the final ECT session in the trial
|
Alle secundaire eindpunten zullen maximaal 1 dag na de laatste ECT sessie binnen de trial worden verkregen. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Yes |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 4 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
End of the trial is defined as the date of data disclosure, after the last data collection of the last patient; namely 1 day after final ECT session within the trial. |
Einde studie is gedefinieerd als moment waarop data base gesloten wordt, dit is op moment wanneer data van de laatst patient verzameld zijn, namelijk 1 dag na de laaste ECT sessie in de trial |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 0 |